AKT/NF-κB inhibitor xanthohumol targets cell growth and angiogenesis in hematologic malignancies

Cancer

Volumn 110, Issue 9, 2007, Pages 2007-2011

  Dell'Eva, Raffaella ^a   Ambrosini, Claudia ^a   Vannini, Nicola ^b   Piaggio, Giovanna ^a   Albini, Adriana ^c   Ferrari, Nicoletta ^a  

^a UNIVERSITY OF GENOA   (Italy)

^b UNIVERSITY OF INSUBRIA   (Italy)

^c IRCCS MULTIMEDICA   (Italy)

Author keywords

Akt; AML; Angiogenesis; CML; Invasion; NF B; Xanthohumol

Indexed keywords

GELATINASE A; GELATINASE B; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; METALLOPROTEINASE; PROTEIN KINASE B; VASCULOTROPIN; XANTHOHUMOL; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; PROPIOPHENONE DERIVATIVE;

ACUTE GRANULOCYTIC LEUKEMIA; ANGIOGENESIS; ANTIANGIOGENIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL ADHESION; CELL INVASION; CELL PROLIFERATION; CELL STRAIN U937; CHRONIC MYELOID LEUKEMIA; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG CYTOTOXICITY; ENDOTHELIUM CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; HEMATOLOGIC MALIGNANCY; HEMATOPOIETIC CELL; HUMAN; HUMAN CELL; LEUKEMIA; LEUKOSTASIS; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; WESTERN BLOTTING; ZYMOGRAPHY; BLOOD DISEASE; CELL MOTION; DOSE RESPONSE; DRUG ANTAGONISM; DRUG EFFECT; NEOVASCULARIZATION (PATHOLOGY); TUMOR CELL LINE;

ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BLOTTING, WESTERN; CELL ADHESION; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; DOSE-RESPONSE RELATIONSHIP, DRUG; HEMATOLOGIC NEOPLASMS; HUMANS; NEOVASCULARIZATION, PATHOLOGIC; NF-KAPPA B; PROPIOPHENONES; PROTO-ONCOGENE PROTEINS C-AKT;

EID: 35648974809     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.23017     Document Type: Article

References (20)

1. Aguayo A, Kantarjian H, Manshouri T, et al. Angiogenesis in acute and chronic leukemias and myelodysplastic syndromes. Blood. 2000;96:2240-2245.
2. Miranda CL, Stevens JF, Helmrich A, et al. Antiproliferative and cytotoxic effects of prenylated flavonoids from hops (Humulus lupulus) in human cancer cell lines. Food Chem Toxicol. 1999;37:271-285.
3. Lust S, Vanhoecke B, Janssens A, Philippe J, Bracke M, Offner F. Xanthohumol kills B-chronic lymphocytic leukemia cells by an apoptotic mechanism. Mol Nutr Food Res. 2005;49:844-850.
4. Albini A, Dell'Eva R, Vene R, et al. Mechanisms of the antiangiogenic activity by the hop flavonoid xanthohumol: NF-kappaB and Akt as targets. FASEB J. 2006;20:527-529.
5. Barnes DJ, Palaiologou D, Panousopoulou E, et al. Bcr-Abl expression levels determine the rate of development of resistance to imatinib mesylate in chronic myeloid leukemia. Cancer Res. 2005;65:8912-8919.
6. Bhatia R, Holtz M, Niu N, et al. Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission after imatinib mesylate treatment. Blood. 2003;101:4701-4707.
7. Braut-Boucher F, Pichon J, Rat P, Adolphe M, Aubery M, Font J. A non-isotopic, highly sensitive, fluorimetric, cell-cell adhesion microplate assay using calcein AM-labeled lymphocytes. J Immunol Methods. 1995;178:41-51.
8. Ries C, Loher F, Zang C, Ismair MG, Petrides PE. Matrix metalloproteinase production by bone marrow mononuclear cells from normal individuals and patients with acute and chronic myeloid leukemia or myelodysplastic syndromes. Clin Cancer Res. 1999;5:1115-1124.
9. Razak K, Allen PD, Kelsey SM, Gutteridge CN, Newland AC. Modulation of CD13 expression during retinoic acid-induced differentiation of HL60 cells. Leuk Res. 1994; 18:629-636.
10. Sekine K, Fujii H, Abe F. Induction of apoptosis by bestatin (ubenimex) in human leukemic cell lines. Leukemia. 1999;13:729-734.
11. Stucki A, Rivier AS, Gikic M, Monai N, Schapira M, Spertini O. Endothelial cell activation by myeloblasts: molecular mechanisms of leukostasis and leukemic cell dissemination. Blood. 2001;97:2121-2129.
12. Braun T, Carvalho G, Fabre C, Grosjean J, Fenaux P, Kroemer G. Targeting NF-kappaB in hematologic malignancies. Cell Death Differ. 2006;13:748-758.
13. Sujobert P, Bardet V, Cornillet-Lefebvre P, et al. Essential role for the p110delta isoform in phosphoinositide 3-kinase activation and cell proliferation in acute myeloid leukemia. Blood. 2005;106:1063-1066.
14. Ramos AM, Fernandez C, Amran D, Sancho P, de Blas E, Aller P. Pharmacologic inhibitors of PI3K/Akt potentiate the apoptotic action of the antileukemic drug arsenic trioxide via glutathione depletion and increased peroxide accumulation in myeloid leukemia cells. Blood. 2005;105:4013-4020.
15. Kornblau SM, Womble M, Qiu YH, et al. Simultaneous activation of multiple signal transduction pathways confers poor prognosis in acute myelogenous leukemia. Blood. 2006;108:2358-2365.
16. Huang S, Pettaway CA, Uehara H, Bucana CD, Fidler IJ. Blockade of NF-kappaB activity in human prostate cancer cells is associated with suppression of angiogenesis, invasion, and metastasis. Oncogene. 2001;20:4188-4197.
17. Bellamy WT, Richter L, Sirjani D, et al. Vascular endothelial cell growth factor is an autocrine promoter of abnormal localized immature myeloid precursors and leukemia progenitor formation in myelodysplastic syndromes. Blood. 2001;97:1427-1434.
18. Verstovsek S, Kantarjian H, Manshouri T, et al. Prognostic significance of cellular vascular endothelial growth factor expression in chronic phase chronic myeloid leukemia. Blood. 2002;99:2265-2267.
19. Fusetti L, Pruneri G, Gobbi A, et al. Human myeloid and lymphoid malignancies in the non-obese diabetic/severe combined immunodeficiency mouse model: frequency of apoptotic cells in solid tumors and efficiency and speed of engraftment correlate with vascular endothelial growth factor production. Cancer Res. 2000;60:2527-2534.
20. Strieter RM. Masters of angiogenesis. Nat Med. 2005;11: 925-927.